BEIJING, Nov. 20, 2018 /PRNewswire/ -- Huiyihuiying (HY), a Chinese medical imaging artificial
The Breast Cancer AI Full Cycle Health Management Platform is committed to the whole cycle of breast cancer diagnosis and treatment, from breast molybdenum target screening to nuclear magnetic diagnosis to pathological diagnosis. The AORTIST 2.0 Aortic AI Cloud platform is to provide a process for the identification of breaks, choosing cardiac stents, and the prognosis of follow-up treatment.
Compared to medical imaging products based on AI 1.0 technology that only cover disease screening and auxiliary diagnosis, the biggest feature of the AI 2.0 products launched by HY is the deep integration of AI and healthcare in three areas: value fusion, data fusion and process fusion.
The new platforms are the result of investment from Intel Investment and Core Kinetic Energy Fund. With these investments and the development of the new platforms, HY will further accelerate the pace of technology and product innovation.
"The concept of Huiyihuiying Medical AI full cycle health management is very good," stated Shiyuan Liu, Chairman of the China Medical Imaging AI Industry, Education and Research Innovation Alliance, after evaluating Huiyihuiying's platforms.
"In order to promote the development of medical imaging AI, it is necessary to integrate multi-border integration of AI enterprises, hospitals and academic institutions so that the new technology of AI will be truly landing," founder and CEO of Huiyihuiying Xiangfei Chai said.
"We believe that the application of multi-modal image data and the full cycle coverage of disease diagnosis and treatment are the trends of AI industry development. There will be more and more diseases in the future cured by AI applications," co-founder of Huiyihuiying, Na Guo said.
View original content:http://www.prnewswire.com/news-releases/huiyihuiying-released-the-ai-full-cycle-management-cloud-platform-based-on-ai-2-0-technology-300753683.html
Subscribe to our Free Newsletters!